propranolol has been researched along with 2019 Novel Coronavirus Disease in 6 studies
Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Propranolol was found to be non-inferior and not superior to topiramate (point estimate of -1." | 3.11 | TOP-PRO study: A randomized double-blind controlled trial of topiramate versus propranolol for prevention of chronic migraine. ( Bansal, L; Chowdhury, D; Datta, D; Duggal, A; Gupta, A; Koul, A; Krishnan, A; Mundra, A, 2022) |
| " Propranolol can commence for most infants in the outpatient setting and the most frequently employed dosing regimen is 1 mg/kg twice daily." | 2.72 | Infantile hemangioma. Part 2: Management. ( Rodríguez Bandera, AL; Sebaratnam, DF; Wargon, O; Wong, LF, 2021) |
| "R-propranolol was as effective as S-propranolol but lacks the latter's undesired β-blocker activity." | 1.91 | R-Propranolol Has Broad-Spectrum Anti-Coronavirus Activity and Suppresses Factors Involved in Pathogenic Angiogenesis. ( Arbiser, JL; Leijs, A; Ninaber, DK; Salgado-Benvindo, C; Snijder, EJ; Tas, A; Thaler, M; van Hemert, MJ, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 6 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chowdhury, D | 1 |
| Bansal, L | 1 |
| Duggal, A | 1 |
| Datta, D | 1 |
| Mundra, A | 1 |
| Krishnan, A | 1 |
| Koul, A | 1 |
| Gupta, A | 1 |
| Thaler, M | 1 |
| Salgado-Benvindo, C | 1 |
| Leijs, A | 1 |
| Tas, A | 1 |
| Ninaber, DK | 1 |
| Arbiser, JL | 1 |
| Snijder, EJ | 1 |
| van Hemert, MJ | 1 |
| Bassi, A | 1 |
| Azzarelli, A | 1 |
| Vaccaro, A | 1 |
| Mazzatenta, C | 1 |
| Mateu-Salat, M | 1 |
| Urgell, E | 1 |
| Chico, A | 1 |
| Hyoju, SK | 1 |
| Zaborina, O | 1 |
| van Goor, H | 1 |
| Sebaratnam, DF | 1 |
| Rodríguez Bandera, AL | 1 |
| Wong, LF | 1 |
| Wargon, O | 1 |
1 review available for propranolol and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Infantile hemangioma. Part 2: Management.
Topics: Adrenergic beta-Antagonists; COVID-19; Hemangioma, Capillary; Humans; Infant; Nevus; Pandemics; Prop | 2021 |
1 trial available for propranolol and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
TOP-PRO study: A randomized double-blind controlled trial of topiramate versus propranolol for prevention of chronic migraine.
Topics: Aged; Communicable Disease Control; COVID-19; Double-Blind Method; Fructose; Humans; Migraine Disord | 2022 |
4 other studies available for propranolol and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
R-Propranolol Has Broad-Spectrum Anti-Coronavirus Activity and Suppresses Factors Involved in Pathogenic Angiogenesis.
Topics: Animals; Antiviral Agents; Cell Line; Chlorocebus aethiops; COVID-19; Humans; Propranolol; SARS-CoV- | 2023 |
At-home dose escalation of propranolol for infantile hemangiomas during the COVID-19 pandemic.
Topics: COVID-19; Hemangioma; Humans; Infant; Propranolol; SARS-CoV-2 | 2020 |
SARS-COV-2 as a trigger for autoimmune disease: report of two cases of Graves' disease after COVID-19.
Topics: Adrenergic beta-Antagonists; Antibodies; Antithyroid Agents; Betacoronavirus; Clinical Laboratory Te | 2020 |
SARS-CoV-2 and the sympathetic immune response: Dampening inflammation with antihypertensive drugs (Clonidine and Propranolol).
Topics: Antihypertensive Agents; Antiviral Agents; Clonidine; Comorbidity; COVID-19; Disease Progression; Hu | 2020 |